Pure Global AI
NCT06351566Not yet recruiting

Effects of Vitamin D3 and Prebiotics Supplementation on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Effects of Vitamin D3 and Prebiotics Supplementation on Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Double-Blind Controlled Trial
Huazhong University of Science and TechnologyClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
Vitamin D3
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Huazhong University of Science and Technology
Timeline & enrollment
Phase
N/A
Start date
Apr 24, 2024
End date
Dec 31, 2025
Enrollment
200 participants
Primary outcome

Glycated hemoglobin (HbA1c),Concentration of blood lipids,Metagenomic analysis of the gut microbiota

Summary

The goal of this randomized, double-blind, placebo-controlled, 6-month supplementation study
 in individuals with type 2 diabetes is to investigate whether taking daily dietary
 supplements of vitamin D3 (1600 IU) or prebiotics (inulin, 10 gram) has beneficial effects on
 cardiovascular disease risk factors.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06351566
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06351566 through Pure Global AI's free database. This phase not specified trial is sponsored by Huazhong University of Science and Technology and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.